文献速递细菌感染、耐药与抗菌药物医院感染防控

亚洲门诊肠外抗菌治疗(OPAT):被忽视的机遇

Outpatient parenteral antibiotic therapy (OPAT) in Asia: missing an opportunity.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

该研究通过同事网络调查了亚洲17个国家171家医疗机构,了解门诊肠外抗菌治疗(OPAT)的提供方式及发展 systematized 服务的意愿。结果显示57%的机构提供门诊肠外抗菌药物,但新加坡以外仅3%的机构具备专科监督的全面服务。作者认为亚洲存在大量未受监管的门诊肠外抗菌治疗问题,需优先发展系统化OPAT。

要点

  • 亚洲17国171家机构中57%提供门诊肠外抗菌治疗,但仅3%具备专科监督的全面服务。
  • 新加坡以外地区缺乏系统化OPAT服务,存在未受监管的治疗风险。
  • 发展系统化OPAT需本地推动者并利用当地激励与需求。

核心结论

  • 亚洲很可能存在大量未受监管的门诊肠外抗菌治疗问题。
  • 亚洲需优先发展全面且系统化的OPAT服务。

研究设计与样本

  • 通过同事及其个人网络对亚洲17个国家的医疗机构进行问卷调查。
  • 调查内容包括当前OPAT提供方式及发展系统化OPAT服务的能力与兴趣。

主要发现

  • 共收到来自17个国家171家医疗机构的回复。
  • 97/171(57%)的机构表示提供门诊肠外抗菌药物。
  • 新加坡以外的162家机构中仅5家(3%)描述具备专科监督的全面服务。

关键数值与推荐

  • 97/171(57%)机构提供门诊肠外抗菌药物。
  • 新加坡以外5/162(3%)机构具备专科监督的全面服务。

临床怎么用

  • 感染科医生应关注本地区门诊肠外抗菌治疗的实施情况。
  • 推动建立系统化OPAT服务,并争取本地支持与资源。

局限性

  • 调查基于同事个人网络,可能存在选择偏倚。
  • 回复来自171家机构,覆盖17个国家,代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Healthcare facilities internationally have grown outpatient parenteral antibiotic administration services for the last few decades. The literature contains publications from dozens of countries describing systematized processes with specialist oversight and their levels of service provision and outcomes. Such descriptions are absent in the majority of Asian countries. We sought to elucidate the extent and nature of outpatient parenteral antibiotic therapy (OPAT) in Asia and to consider the ramifications and opportunities for improvement. METHODS: Utilizing colleagues and their personal networks, we surveyed healthcare facilities across 17 countries in Asia to ascertain the current means (if any) of providing OPAT. In that survey we also sought to explore the capacity and interest of these facilities in developing systematized OPAT services. RESULTS: Responses were received from 171 different healthcare facilities from 17 countries. Most (97/171, 57%) stated that they administer outpatient parenteral antibiotics, but only 5 of 162 facilities (3%) outside of Singapore described comprehensive services with specialist oversight. CONCLUSIONS: There is very likely a large unrecognized problem of unchecked outpatient parenteral antibiotic administration in Asia. Developing comprehensive and systematized OPAT in Asia is needed as a priority in an environment in which the infectious diseases community is demanding broad stewardship approaches. There are nonetheless challenges in establishing and sustaining OPAT programmes. Local champions and leverage off identified local incentives and needs are key to regional advancement.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Fisher D, Michaels J, Hase R, et al. Outpatient parenteral antibiotic therapy (OPAT) in Asia: missing an opportunity. J Antimicrob Chemother. 2017. PMID: 28077673. doi:10.1093/jac/dkw551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。